Literature DB >> 9697976

Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S.

M Yasue1, T Yokota, M Fukada, T Takai, M Suko, H Okudaira, Y Okumura.   

Abstract

C8/119S is a mutant of recombinant Der f 2 (rDer f 2), and lacks a disulphide bond possessed by wild-type rDer f 2. In humans and mice, C8/119S has a very weak IgE-binding capacity compared with the wild-type, but possesses a T cell reactivity comparable to that of the wild-type. C8/119S may thus be a safe immunotherapeutic agent for house dust mite allergy. The aim of the present study was to evaluate whether the intranasal administration of C8/119S could suppress an immediate allergic reaction in mice sensitized with wild-type rDer f 2, possessing an allergic activity comparable to native counterparts purified from mite extract. Seven-week-old male A/J mice were immunized with wild-type rDer f 2 four times, and then intranasally administered 0.2-2 microg of wild-type, 0.2-20 microg of C8/119S, or PBS alone, three times a week for 4 weeks. Seven days after the last administration, the mice were examined for an immediate allergic reaction. The animals administered 2 microg of C8/119S (C2.0 group) showed significantly reduced immediate bronchoconstriction provoked by the i.v. injection of 1 and 10 microg of wild-type rDer f 2, compared with the PBS-treated mice. Similar results were obtained when we examined mice 10 weeks after the last administration. The reactions in the other groups given wild-type or C8/119S also tended to decrease in severity in comparison with the animals of the PBS group. The allergic phenotypes of the T cells, B cells, and basophils in the C2.0 group were shifted to that of naive mice without immunization. We conclude that C8/119S has hyposensitizing activities in mice sensitized with wild-type rDer f 2. C8/119S may be useful for immunotherapy of house dust mite allergy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697976      PMCID: PMC1905018          DOI: 10.1046/j.1365-2249.1998.00616.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  79 in total

1.  Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells.

Authors:  K Rajakulasingam; S R Durham; F O'Brien; M Humbert; L T Barata; L Reece; A B Kay; J A Grant
Journal:  J Allergy Clin Immunol       Date:  1997-07       Impact factor: 10.793

2.  Study on changes in the level of serum IL-4 and soluble CD 23(s-CD23) with immunotherapy in nasal allergy patients.

Authors:  H Ito; M Suzuki; S Mamiya; I Takagi; S Baba
Journal:  Acta Otolaryngol Suppl       Date:  1996

3.  IgE antibody up-regulates high affinity IgE binding on murine bone marrow-derived mast cells.

Authors:  C Hsu; D MacGlashan
Journal:  Immunol Lett       Date:  1996-09       Impact factor: 3.685

4.  Discontinuing venom immunotherapy: outcome after five years.

Authors:  D B Golden; K A Kwiterovich; A Kagey-Sobotka; M D Valentine; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1996-02       Impact factor: 10.793

5.  Interleukin-4 and low-affinity receptor for IgE on B cells in peripheral blood of patients with atopic bronchial asthma.

Authors:  C S Park; D J Ra; S M Lee; S W Jeong; S Uh; H T Kim; Y H Kim
Journal:  J Allergy Clin Immunol       Date:  1996-05       Impact factor: 10.793

6.  Treatment of cat allergy with T-cell reactive peptides.

Authors:  P S Norman; J L Ohman; A A Long; P S Creticos; M A Gefter; Z Shaked; R A Wood; P A Eggleston; K B Hafner; P Rao; L M Lichtenstein; N H Jones; C F Nicodemus
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

7.  IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity.

Authors:  M Humbert; S R Durham; S Ying; P Kimmitt; J Barkans; B Assoufi; R Pfister; G Menz; D S Robinson; A B Kay; C J Corrigan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

8.  T cells are the predominant source of interleukin-5 but not interleukin-4 mRNA expression in the lungs of antigen-challenged allergic mice.

Authors:  C G Garlisi; A Falcone; M M Billah; R W Egan; S P Umland
Journal:  Am J Respir Cell Mol Biol       Date:  1996-09       Impact factor: 6.914

9.  Decrease in CD23+ B lymphocytes and clinical outcome in asthmatic patients receiving specific rush immunotherapy.

Authors:  M Kljaic-Turkalj; B Cvoriscec; N Tudoric; A Stipic-Markovic; S Rabatic; A Trescec; A Gagro; D Dekaris
Journal:  Int Arch Allergy Immunol       Date:  1996-10       Impact factor: 2.749

10.  Germinal center formation and local immunoglobulin E (IgE) production in the lung after an airway antigenic challenge.

Authors:  Y Chvatchko; M H Kosco-Vilbois; S Herren; J Lefort; J Y Bonnefoy
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Murine models for mucosal tolerance in allergy.

Authors:  Ursula Smole; Irma Schabussova; Winfried F Pickl; Ursula Wiedermann
Journal:  Semin Immunol       Date:  2017-08-12       Impact factor: 11.130

Review 2.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

3.  Type 2 immune-inducing helminth vaccination maintains protective efficacy in the setting of repeated parasite exposures.

Authors:  Marc P Hübner; Marina N Torrero; Edward Mitre
Journal:  Vaccine       Date:  2009-12-23       Impact factor: 3.641

Review 4.  Genetically engineered vaccines.

Authors:  Wayne R Thomas; Belinda J Hales; Wendy-Anne Smith
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.919

5.  Influence of the Adjuvants and Genetic Background on the Asthma Model Using Recombinant Der f 2 in Mice.

Authors:  Yoon-Seok Chang; Yoon-Keun Kim; Seong Gyu Jeon; Sae-Hoon Kim; Sun-Sin Kim; Heung-Woo Park; Kyung-Up Min; You-Young Kim; Sang-Heon Cho
Journal:  Immune Netw       Date:  2013-12-20       Impact factor: 6.303

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.